

Syneos Health Recruits High-Performing Sites to Beat Forecasted Trial Start Date

Syneos Health worked with Verana Health to remediate patient enrollment challenges in a substantial retinal clinical study, involving over 2,000 patients across multiple sites. Leveraging real-world data (RWD) from Verana Health's partner, the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), and site identification services, the collaboration focused on requalifying existing sites and identifying new, high-performing ones. This enabled Syneos Health to streamline recruitment, improve site engagement, and maintain momentum despite delays. By strategically integrating Verana Health's data insights, Syneos Health not only achieved its enrollment goals, thereby increasing the chances of study success, but also saved costs with minimal delays and maximum efficiency.

Problem/Challenge

- Syneos Health needed to enroll patients for a large retinal clinical trial, involving over 2,000 participants across nearly 200 sites.
- Post-COVID-19 dynamics disrupted site activation and recruitment, slowing enrollment to unsustainable levels. Many existing sites underperformed, and identifying new ones proved increasingly difficult due to shifting site dynamics and patient demographics.
- Further delays threatened to extend the enrollment timeline, bearing costs and jeopardizing the study's overall success.

Verana's data was a game changer in meeting an ambitious goal for one of the largest retina studies. By identifying high-quality sites and optimizing patient recruitment, they helped reduce the enrollment timeline by two months"

Laszlo Bekesi
Vice President, Syneos Health



Solution/Partnering with Verana

- Syneos Health collaborated with Verana Health to leverage the IRIS Registry and site identification services, focusing on requalifying underperforming sites and identifying untapped, high-volume sites for the retinal study.
- Verana Health's data-driven insights and expertise enabled a thorough cross-check of the 200 committed sites against its registry, identifying nearly 40 additional sites with relevant patient populations.
- By streamlining site feasibility and optimizing recruitment, Syneos Health expanded its network and maintained momentum, ensuring a more efficient and successful enrollment process for the trial.

Results

- By cross-checking site lists with Verana Health's RWD network, nearly 40 new sites were identified and activated.
- This effort enabled Syneos Health to meet its 2,000-patient enrollment target earlier than forecasted.
- Accelerating enrollment timelines saved the Sponsor and Syneos Health potential unforeseen costs, reduced site burden and ensured the study maintained its competitive edge in the retinal therapy space.

By cross-checking
site lists with Verana
Health's RWD
network, nearly
40 new sites
were identified
and activated.



About Verana Health

Verana Health® is revolutionizing patient care and clinical research by unlocking the potential of real-world data. Verana Health has an exclusive real-world data network of 90 million de-identified patients from more than 20,000 clinicians, stemming from its exclusive data partnerships with leading medical societies. Verana Health harnesses deep expertise, secure advanced technology, and direct access to exclusive, near real-time data sources to deliver actionable quality insights that help companies make sense of the data. For more information, visit www.veranahealth.com